Cantor expands healthcare and biotech research

Cantor Fitzgerald

Cantor Fitzgerald has expanded its healthcare equity research team with the addition of Bill Tanner as a senior research analyst covering biotechnology and Steven Halper as a senior research analyst covering healthcare services.

Mr. Tanner and Mr. Halper are managing directors based in New York and will report to Mara Goldstein, director of research.

“Thanks to an in-depth understanding of the biotech and healthcare services, Bill and Steven’s addition to the team underscores Cantor Fitzgerald’s commitment to enhancing its healthcare research franchise and to complementing its existing biotechnology and healthcare services coverage,” Ms. Goldstein said in a statement.

Mr. Tanner was previously with Guggenheim Securities, where he was a senior biotechnology analyst. Prior to Guggenheim, he was at Lazard Capital Markets, Leerink Swann and SG Cowen, all firms with a significant focus on the healthcare sector.

Prior to joining Cantor, Mr. Halper focused on healthcare information technology, managed care and pharmaceutical service industries at several major firms, including FBR Capital Markets, and previously Lazard Capital Markets.